ClinicalTrials.gg
CompletedNCT04247074READY-3Updated Sep 6, 2023Results posted

Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

A Phase 3 interventional study of botulinum toxin neuromodulator and Placebo in Glabellar Frown Lines (GL) and Lateral Canthal Lines (LCL), sponsored by Galderma R&D. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.

02

Conditions studied

  • Glabellar Frown Lines (GL)
  • Lateral Canthal Lines (LCL)
03

In context

Lead sponsor

Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female 18 years of age or older.
  2. Moderate to severe LCL at maximum smile as assessed by the Investigator.
  3. Moderate to severe LCL at maximum smile as assessed by the subject.
  4. Moderate to severe GL at maximum frown as assessed by the Investigator.
  5. Moderate to severe GL at maximum frown as assessed by the subject

Exclusion criteria

Exclusion Criteria:

  1. Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.
  2. Female who is pregnant, breast feeding, or intends to conceive a child during the study.
  3. Known allergy or to any component of the product (QM1114-DP).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
413 participants (actual)

Study arms

  • Experimental
    QM1114-DP in the LCL + Placebo in the GL

    QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection

    Biological: botulinum toxin neuromodulator · Biological: Placebo

  • Placebo comparator
    Placebo in the LCL and GL

    A buffered solution; Mode of administration: intramuscular injection

    Biological: Placebo

  • Experimental
    Placebo in the LCL + QM1114-DP in the GL

    QM1114-DP, a Botulinum Toxin Type A (BoNT-A) or placebo Mode of administration: intramuscular injection

    Biological: botulinum toxin neuromodulator · Biological: Placebo

  • Experimental
    QM1114-DP in the LCL + GL

    QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection

    Biological: botulinum toxin neuromodulator

Interventions

  • QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL

    Also known as: QM1114-DP

  • BiologicalPlacebo

    Placebo will be injected into either the LCL, GL, or both the LCL and GL

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown

    Investigator 4-point Photographic Scale of Glabellar Line Severity represents the severity of GL from none (grade 0), mild (grade 1), moderate (grade 2) to severe (grade 3). Each grade is depicted by an individual photograph and a descriptive text. The Investigators used the 4-point Photographic Scale for direct, live comparison with the subject's face at maximum frown. Subjects made their assessment of glabellar line severity independently of the Investigator's assessment. Subjects were asked to evaluate their GL at maximum frown by grading the GL severity from none (grade 0, smooth skin), mild (grade 1, fairly smooth skin), moderate (grade 2, frown lines) to severe (grade 3, deep frown lines).

    Time frame: Month 1

  2. Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Lines Investigator and Subject Assessments at Maximum Smile

    Investigator 4-point Photographic Scale of Lateral Canthal Line represents LCL severities from none (grade 0), mild (grade 1), moderate (grade 2), to severe (grade 3). Each grade is also depicted by an individual photograph and descriptive text. The Investigators used the LCL-ILA for direct, live comparison with the subject's face for grading LCL severity. Left and right LCL were assessed at maximum smile. Subject 4-point Photographic Scale of Lateral Canthal Line Severity represents LCL severities from Level 0, Level 1, Level 2, to Level 3. Each grade is also depicted by an individual photograph and descriptive text. Subjects made their assessments independently of the Investigator's assessment. Subjects evaluated their LCL severity (left and right side separately) at maximum smile.

    Time frame: Month 1

Secondary outcomes

  1. Percentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown

    Time frame: Month 1

  2. Percentage of Subjects Who Achieve Grade 0 or 1 in Lateral Canthal Line Investigator Scale at Maximum Smile.

    Time frame: Month 1

07

Results

Posted Sep 6, 2023

Participant flow

Participant flow — Overall Study
MilestoneQM1114-DP in the LCL + Placebo in the GLPlacebo in the LCL and GLPlacebo in the LCL + QM1114-DP in the GLQM1114-DP in the LCL + GL
Started12659113115
Completed12152106107
Not completed5778

Outcome measures

PrimaryPercentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown

Investigator 4-point Photographic Scale of Glabellar Line Severity represents the severity of GL from none (grade 0), mild (grade 1), moderate (grade 2) to severe (grade 3). Each grade is depicted by an individual photograph and a descriptive text. The Investigators used the 4-point Photographic Scale for direct, live comparison with the subject's face at maximum frown. Subjects made their assessment of glabellar line severity independently of the Investigator's assessment. Subjects were asked to evaluate their GL at maximum frown by grading the GL severity from none (grade 0, smooth skin), mild (grade 1, fairly smooth skin), moderate (grade 2, frown lines) to severe (grade 3, deep frown lines).

Time frame:
Month 1
Reported as:
Count of participants · Participants
Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown
ParticipantsPlacebo in the LCL and GLPlacebo in the LCL + QM1114-DP in the GLQM1114-DP in the LCL + GL (GL Data)
Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown07578
Statistical analysis
  • Placebo in the LCL and GL vs Placebo in the LCL + QM1114-DP in the GL vs QM1114-DP in the LCL + GL (GL Data) · Cochran-Mantel-Haenszel · p = <0.001
PrimaryPercentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Lines Investigator and Subject Assessments at Maximum Smile

Investigator 4-point Photographic Scale of Lateral Canthal Line represents LCL severities from none (grade 0), mild (grade 1), moderate (grade 2), to severe (grade 3). Each grade is also depicted by an individual photograph and descriptive text. The Investigators used the LCL-ILA for direct, live comparison with the subject's face for grading LCL severity. Left and right LCL were assessed at maximum smile. Subject 4-point Photographic Scale of Lateral Canthal Line Severity represents LCL severities from Level 0, Level 1, Level 2, to Level 3. Each grade is also depicted by an individual photograph and descriptive text. Subjects made their assessments independently of the Investigator's assessment. Subjects evaluated their LCL severity (left and right side separately) at maximum smile.

Time frame:
Month 1
Reported as:
Count of participants · Participants
Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Lines Investigator and Subject Assessments at Maximum Smile
ParticipantsQM1114-DP in the LCL + Placebo in the GLPlacebo in the LCL and GLQM1114-DP in the LCL + GL (LCL Data)
Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Lateral Canthal Lines Investigator and Subject Assessments at Maximum Smile53059
Statistical analysis
  • QM1114-DP in the LCL + Placebo in the GL vs Placebo in the LCL and GL vs QM1114-DP in the LCL + GL (LCL Data) · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown
Time frame:
Month 1
Reported as:
Count of participants · Participants
Percentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown
ParticipantsPlacebo in the LCL and GLPlacebo in the LCL + QM1114-DP in the GLQM1114-DP in the LCL + GL
Percentage of Subjects With a 0 or 1 on the Glabellar Lines Investigator Scale at Maximum Frown197102
Statistical analysis
  • Placebo in the LCL and GL vs Placebo in the LCL + QM1114-DP in the GL vs QM1114-DP in the LCL + GL · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Subjects Who Achieve Grade 0 or 1 in Lateral Canthal Line Investigator Scale at Maximum Smile.
Time frame:
Month 1
Reported as:
Count of participants · Participants
Percentage of Subjects Who Achieve Grade 0 or 1 in Lateral Canthal Line Investigator Scale at Maximum Smile.
ParticipantsQM1114-DP in the LCL + Placebo in the GLPlacebo in the LCL and GLQM1114-DP in the LCL + GL (LCL Data)
Percentage of Subjects Who Achieve Grade 0 or 1 in Lateral Canthal Line Investigator Scale at Maximum Smile.891089
Statistical analysis
  • QM1114-DP in the LCL + Placebo in the GL vs Placebo in the LCL and GL vs QM1114-DP in the LCL + GL (LCL Data) · Cochran-Mantel-Haenszel · p = <0.001

Adverse events

Collected over 6 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
QM1114-DP in the LCL + Placebo in the GL0/123 (0%)0/123 (0%)9/123 (7.3%)
Placebo in the LCL and GL0/58 (0%)1/58 (1.7%)6/58 (10.3%)
Placebo in the LCL + QM1114-DP in the GL0/116 (0%)1/116 (0.9%)18/116 (15.5%)
QM1114-DP in the LCL + GL0/115 (0%)1/115 (0.9%)9/115 (7.8%)
Most frequent serious events
Most frequent serious events
EventQM1114-DP in the LCL + Placebo in the GLPlacebo in the LCL and GLPlacebo in the LCL + QM1114-DP in the GLQM1114-DP in the LCL + GL
Hypertensive emergencyVascular disorders0/1231/580/1160/115
Enterocutaneous fistulaGastrointestinal disorders0/1230/580/1161/115
AppendicitisInfections and infestations0/1230/581/1160/115
DehydrationMetabolism and nutrition disorders0/1230/581/1160/115
Most frequent other events
Most frequent other events
EventQM1114-DP in the LCL + Placebo in the GLPlacebo in the LCL and GLPlacebo in the LCL + QM1114-DP in the GLQM1114-DP in the LCL + GL
COVID-19Infections and infestations4/1234/586/1163/115
HeadacheNervous system disorders3/1230/586/1164/115
Injection site painGeneral disorders1/1232/580/1160/115
Eyelid ptosisEye disorders0/1230/583/1160/115
Injection site bruisingGeneral disorders2/1231/583/1162/115

Baseline characteristics

Age, Continuous
Age, Continuous(years)QM1114-DP in the LCL + Placebo in the GLPlacebo in the LCL and GLPlacebo in the LCL + QM1114-DP in the GLQM1114-DP in the LCL + GLTotal
Mean50.3 ± 10.4449.8 ± 50.050.4 ± 9.7750.5 ± 10.6350.3 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)QM1114-DP in the LCL + Placebo in the GLPlacebo in the LCL and GLPlacebo in the LCL + QM1114-DP in the GLQM1114-DP in the LCL + GLTotal
Female1135510397368
Male133101844
Race (NIH/OMB)
Race (NIH/OMB)(Participants)QM1114-DP in the LCL + Placebo in the GLPlacebo in the LCL and GLPlacebo in the LCL + QM1114-DP in the GLQM1114-DP in the LCL + GLTotal
American Indian or Alaska Native00000
Asian10102
Native Hawaiian or Other Pacific Islander01001
Black or African American627621
White11554105105379
More than one race10023
Unknown or Not Reported31026
08

Study locations

12 sites
  • Clinical Testing of Beverly Hills
    Encino, California 91436, United States
  • Ava MD
    Santa Monica, California 90404, United States
  • Skin Care & Laser Physicians of Beverly Hills
    West Hollywood, California 90069, United States
  • Center for Clinical and Cosmetic Research
    Aventura, Florida 33180, United States
  • Baumann Cosmetic & Research Institute, Inc
    Miami, Florida 33137, United States
  • Washington Institute of Dermatologic Laser Surgery
    Chevy Chase, Maryland 20815, United States
  • Maryland Dermatology, Laser, Skin & Vein Institute
    Hunt Valley, Maryland 21030, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • Lorenc Aesthetic Plastic Surgery Center
    New York, New York 10028, United States
  • Elite Aesthetic Research
    Cincinnati, Ohio 45236, United States
  • The Westlake Dermatology Clinical Research
    Austin, Texas 78746, United States
  • Bertucci Medspa, Inc
    Woodbridge, Ontario L4L 8E2, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Oct 2020, 7 months.

Results were first posted in Sep 2023, 2 years 11 months after primary completion. A results delay was requested in May 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2020
First posted
Jan 29, 2020
StartActual
Feb 10, 2020
Primary completionActual
Oct 2, 2020
CompletionActual
Feb 26, 2021
Results delay requested
May 26, 2021
Results first posted
Sep 6, 2023
Last update
Sep 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04247074
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jan 29, 2020
Start date
Feb 10, 2020
Primary completion
Oct 2, 2020
Completion
Feb 26, 2021
Results posted
Sep 6, 2023
Last update
Sep 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion